Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (May 2019)
28 slides from Genetic Technologies's investor presentation, May 2, 2019
Slide 1: Genetic Technologies Company Profile
For personal use only Genetic Technologies Company Profile 01 May 2019
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 3: Who we are
Who we are For personal use only Research and Development leader in the genomics sector • Developing and commercialising a • Progressive R&D and suite of genetic risk assessment commercialisation partner to products to prevent morbidity and • Universities mortality across a range of diseases • Resea
Slide 4: Our vision
Our vision For personal use only • To improve health outcomes for people around the world by providing individuals and their physicians with the risk assessment tools to develop personalised health management plans for early detection and treatment of chronic disease • To continually strive to maint
Slide 5: GTG corporate overview
GTG corporate overview For personal use only 5
Slide 6: Our genetic test predicts a woman's risk of developing breast cancer
Our genetic test predicts a woman’s risk of developing breast cancer For personal use only BREVAGenplus® is a first-to-market, clinically validated genetic risk assessment for non-hereditary (sporadic) breast cancer Simple cheek swab that helps determine a woman’s risk of developing breast cancer Fi
Slide 7: Precision medicine
Precision medicine For personal use only • 1 in eight women will get breast cancer in their lifetime • Screening programs that test all women at the same intervals will be overscreening 7 women and underscreening 1 woman • Our risk assessment test offers health policy regulators and clinicians the p
Slide 8: Early detection = better outcomes
Early detection = better outcomes For personal use only 5 year survival rates dramatically improve when breast cancer is diagnosed before spreading to other parts of the body 8 https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
Slide 9: Early diagnosis = less expensive treatment
Early diagnosis = less expensive treatment For personal use only Stage I $ 55,000 First year treatment costs for Stage II $103,000 breast cancer Stage III and IV $127,000 USD, study based on US patients, 2003-2010 9 https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0207993.t00
Slide 10: Targeted screening and prevention
Targeted screening and prevention For personal use only Screening More frequent mammograms or MRIs BREVAGenplus® enables the targeting of limited resources to Medication women who are Selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) most likely to develop breast cancer. L
Slide 11: We are developing new genetic screening tests
We are developing new genetic screening tests For personal use only 2Q 2019 3Q 2019 4Q 2019 2020 * Tests are developed and market launch is scheduled. 11
Slide 12: GTG's enhanced breast cancer test covers 95% of women
GTG’s enhanced breast cancer test covers 95% of women For personal use only Only 5% of women with breast cancer have a pathogenic variant, such as BRCA • 85% of women have no family history of breast cancer • 10% have a family history but no pathogenic variants, such as BRCA Our test covers 95% of w
Slide 13: GTG has developed a world-first polygenic risk test for colon cancer
GTG has developed a world-first polygenic risk test for colon cancer For personal use only Risk stratification enables precision screening and Easy-to-use test solves personalised prevention the compliance problem Clinically actionable results 5-year, 10-year and lifetime risk Informs screening and
Slide 14: Collaboration with world-leading partners
For personal use only Collaboration with world-leading partners
Slide 15: Development of Commercialization Strategy with TGen
Development of Commercialization Strategy with TGen For personal use only MOU Signed GTG and TGen will cooperate in the development of a commercialisation strategy and infrastructure development for a suite of polygenic risk tests to be made available in the US market. The collaboration will be wide
Slide 16: Translational Genomics Research Institute (TGen): Collaborative Network
Translational Genomics Research Institute (TGen): Collaborative Network For personal use only Background Areas of Disease Focus - Est. 2002 Health Care Partners: - Oncology - Non-profit (501c3) - Neurology Community hospitals, health care - Rare Childhood Disorders - Patient-focused clinical & basic
Slide 17: The Distribution Channel
The Distribution Channel For personal use only The TGen collaboration opens up a number of potential distribution channels: I. Major US Healthcare Systems Distribution opportunity: Health care system test availability II. National Cancer Centers Distribution opportunity: Testing of cancer patients a
Slide 18: The Distribution Channel
The Distribution Channel For personal use only V. Disease consortiums Distribution opportunity: Clinical validity and clinical utility studies VI. State Government Distribution opportunity: Public health department “endorsement;” Public policy; Clinical utility studies VII. Federal Government Distri
Slide 19: The Tgen Clinical Laboratory
The Tgen Clinical Laboratory For personal use only • Founded in 2011 • CLIA certified in 2013 • CAP certified 2014 • Provided some of the world’s first clinical studies for personalized cancer treatment • Spun out from TGen in 2014, provides commercial access to personalized cancer treatment via gen
Slide 20: Collaboration is a key market advantage
Collaboration is a key market advantage For personal use only The University of Melbourne • Australia’s peak research-intensive institution, ranked 32nd globally Our collaboration with The University of Melbourne was awarded an NHMRC grant • Research investigation to assess the improvement Professor
Slide 21: Research into clinical applications
Research into clinical applications For personal use only GTG has an agreement in place with Memorial Sloan Kettering (MSK) and University of Cambridge • The research is led by Mark E. Robson, MD, Chief of Breast Medicine Service, Memorial Sloan Kettering • MSK is the world’s oldest and largest canc
Slide 22: Other key partnerships
Other key partnerships For personal use only Ohio State University (Columbus, Ohio) • Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations • Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast ca
Slide 23: Intellectual property is our advantage
Intellectual property is our advantage For personal use only GTG has a strong patent portfolio covering the breast cancer risk assessment test 5 Patents granted in the US 5 Patents granted in China • Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of • Patent Nos. 200680051710.0; 20131
Slide 24: Scientific authority
Scientific authority For personal use only Dr. Richard Allman, Chief Scientific Officer • Strong publication record in genetic epidemiology across multiple disease categories • Collaboration for peer review and statistical validation BSc Microbiology, PhD Microbiology (Flow Cytometric Analysis of Ba
Slide 25: Hainan Medical Pilot Zone
Hainan Medical Pilot Zone For personal use only GTG has established its Asian operations with the formation of Genetic Technologies HK and Hainan Aocheng Genetic Technologies • Part of the Hainan Free Trade Zone Initiative • Best-in-class medical care, physicians, treatments, technology and cutting-
Slide 26: GTG's approach aligns with Healthy China 2030
GTG’s approach aligns with Healthy China 2030 For personal use only Healthy China 2030 is the Chinese Central Government’s comprehensive healthcare policy for 1.5 billion people • Disease prevention is a means of controlling costs • Chinese government can enforce compliance with preventive healthcar
Slide 27: Next Steps in China
Next Steps in China For personal use only Develop collaborative Deliver the benefits of genetic relationships screening • Clinical validation • Go-to-market plan for additional genetic • Regulatory approval screening tests • Commercial channels • Engagement with key opinion leaders • Laboratory test
Slide 28: Thank you
Thank you For personal use only Paul Kasian Chairman and CEO paul.kasian@gtglabs.com www.gtgcorporate.com 28
Genetic Technologies — Investor Presentation (May 2019) on 6ix